Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,607,065
  • Shares Outstanding, K 190,583
  • Annual Sales, $ 2,419 M
  • Annual Income, $ 167,650 K
  • EBIT $ 381 M
  • EBITDA $ 476 M
  • 60-Month Beta 0.31
  • Price/Sales 5.20
  • Price/Cash Flow 36.91
  • Price/Book 2.33

Options Overview Details

View History
  • Implied Volatility 26.55% ( -1.75%)
  • Historical Volatility 19.18%
  • IV Percentile 25%
  • IV Rank 15.41%
  • IV High 48.42% on 08/05/24
  • IV Low 22.57% on 04/26/24
  • Put/Call Vol Ratio 0.35
  • Today's Volume 163
  • Volume Avg (30-Day) 2,477
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 46,490
  • Open Int (30-Day) 46,646

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.55
  • Number of Estimates 12
  • High Estimate 0.63
  • Low Estimate 0.49
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +111.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.35 +2.26%
on 10/31/24
70.98 -5.85%
on 10/25/24
-2.14 (-3.10%)
since 10/07/24
3-Month
65.35 +2.26%
on 10/31/24
94.85 -29.55%
on 08/20/24
-19.48 (-22.57%)
since 08/07/24
52-Week
65.35 +2.26%
on 10/31/24
99.56 -32.88%
on 12/14/23
-18.67 (-21.83%)
since 11/07/23

Most Recent Stories

More News
BioMarin: Q3 Earnings Snapshot

BioMarin: Q3 Earnings Snapshot

BMRN : 66.63 (+0.73%)
2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

NVDA : 147.93 (+1.59%)
$NASX : 19,230.13 (+1.30%)
$SPX : 5,966.61 (+0.63%)
MU : 113.08 (+1.12%)
BMRN : 66.63 (+0.73%)
Do Options Traders Know Something About BioMarin (BMRN) Stock We Don't?

Investors in BioMarin Pharmaceutical Inc. BMRN need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 18, 2024 $55.00 Call had some of the highest...

BMRN : 66.63 (+0.73%)
3 Oversold Stocks with Big RSI Rebound Potential

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

HUM : 286.60 (-0.66%)
ASND : 127.39 (-1.52%)
BMRN : 66.63 (+0.73%)
ELV : 427.28 (-0.38%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 101.47 (+0.73%)
NVS : 106.92 (+0.10%)
KTRA : 0.2154 (-6.31%)
RKV.VN : 0.080 (unch)
RHHBY : 38.1150 (+0.91%)
XBIT : 7.76 (-5.94%)
BMRN : 66.63 (+0.73%)
AZN : 64.20 (+0.55%)
Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

VRTX : 500.84 (+1.46%)
$NASX : 19,230.13 (+1.30%)
BMRN : 66.63 (+0.73%)
Stock Index Futures Tread Water as Investors Brace for Fed Minutes and Powell’s Speech

September S&P 500 E-Mini futures (ESU24) are up +0.01%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.09% this morning as market participants geared up for the release of the minutes of the...

ESU24 : 5,699.99s (-0.31%)
NQU24 : 19,808.01s (-0.21%)
ZIM : 25.16 (+4.62%)
AMD : 148.70 (+2.48%)
MCD : 295.25 (+0.43%)
HPQ : 37.12 (+0.57%)
LOW : 264.91 (+1.21%)
MDT : 88.42 (-1.88%)
KEYS : 164.28 (+1.50%)
TOL : 153.29 (+1.29%)
AS : 19.15 (+6.09%)
TTNP : 4.15 (+1.22%)
CSX, Caterpillar rise; ZoomInfo, Teradata fall, Tuesday, 8/6/2024

Stocks that traded heavily or had substantial price changes on Tuesday: CSX, Caterpillar rise; ZoomInfo, Teradata fall

YUMC : 51.42 (+3.19%)
LCID : 2.21 (+3.76%)
BMRN : 66.63 (+0.73%)
PLTR : 54.51 (-1.84%)
CSX : 35.61 (-3.44%)
TDC : 29.05 (-0.95%)
ZI : 11.76 (-0.68%)
BioMarin: Q2 Earnings Snapshot

BioMarin: Q2 Earnings Snapshot

BMRN : 66.63 (+0.73%)
4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Plain-as-day bargains can still be found, even with the innovation-fueled Nasdaq Composite powering to a fresh all-time high.

COMP : 6.91 (+6.97%)
$NASX : 19,230.13 (+1.30%)
META : 591.86 (+3.46%)
FVRR : 29.59 (+0.17%)
BMRN : 66.63 (+0.73%)
WDC : 70.60 (+0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 69.11
2nd Resistance Point 68.38
1st Resistance Point 67.26
Last Price 66.63
1st Support Level 65.41
2nd Support Level 64.68
3rd Support Level 63.56

See More

52-Week High 99.56
Fibonacci 61.8% 86.49
Fibonacci 50% 82.46
Fibonacci 38.2% 78.42
Last Price 66.63
52-Week Low 65.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar